Sterling Accuris Achieves Over Rs 200 Cr in Revenue for FY25 and Records Positive EBITDA
Sterling Accuris Diagnostics managed 22% year-on-year growth, turning EBITDA positive in FY25.
Sterling Accuris Diagnostics managed 22% year-on-year growth, turning EBITDA positive in FY25.
Sterling Accuris Diagnostics achieved 22% growth in FY25, narrowing losses and turning EBITDA positive.